

Neuromap® Al-Based Functional & Psychological Brain Report Developed by Dr. Alptekin Aydin

Neuromap® integrates advanced AI technology, cutting-edge algorithms, comprehensive & highly personalized brain reports.

LONDON, ENFIELD, UNITED KINGDOM, October 7, 2024 /EINPresswire.com/ --Cosmos Healthcare Launches Neuromap®: A Groundbreaking Al-Based Holistic Functional & Psychological Brain Report for Personalized Healthcare

Harnessing the power of AI to revolutionize brain function analysis and personalized treatment planning.



Dr Alptekin Aydin develop neuromap with his team

London, Cosmos Healthcare, a leader in innovative healthcare solutions, is proud to announce the launch of Neuromap[®], a revolutionary Al-based system designed to generate holistic reports



Neuromap®: A
Groundbreaking Al-Based
Holistic Functional &
Psychological Brain Report"
Harnessing the power of Al for
personalized Functional Brain
Reporting.

from quantitative EEG (qEEG) data. Neuromap® offers personalized treatment recommendations tailored to individual brain function and overall health, paving the way for more accurate diagnoses and customized healthcare strategies.

Developed by Cosmos Healthcare's expert team led by Dr. Alptekin Aydin, Neuromap® integrates advanced artificial intelligence (AI) technology with patient qEEG scans and other critical health information. The system's cutting-edge

algorithms identify patterns and correlations that were previously undetectable through conventional methods, producing comprehensive reports that are highly personalized to the individual.

"The integration of AI into healthcare is transforming the landscape of personalized treatment," said Dr. Alptekin Aydin, lead developer and Chief executive Officer at Cosmos Healthcare. "Neuromap® harnesses the power of AI to provide an in-depth understanding of brain activity, making it possible to offer treatment recommendations that are truly tailored to each patient's unique neurological profile."

Key Features of Neuromap[®] Neuromap[®] incorporates a wide range of features to provide a holistic overview of a patient's brain function



and health needs. These reports are designed not only for medical professionals but also for patients and their families to understand and engage with the treatment process.

Al-Based Diagnosis and Recommendations: Neuromap® utilizes Al to detect paroxysmal activity in EEG data, which is crucial for diagnosing conditions like epilepsy. Based on these findings, the system generates qEEG-guided rehabilitation and treatment plans for various neurological conditions.

Personalized Recommendations: The reports include custom-tailored suggestions for therapy, education, sports, and nutrition plans, each based on the individual's unique brain function analysis. This level of personalization ensures that treatments are more effective and responsive to the patient's specific needs.

Family Support and Home Adjustments: Neuromap® emphasizes the importance of family involvement in the treatment process. The reports provide strategies for improving communication and support within the family unit, as well as recommendations for modifying the home environment to enhance rehabilitation outcomes.

<u>Sports, Nutrition, and Lifestyle Plans</u>: The holistic approach includes detailed nutrition advice—suggesting foods to eat, foods to avoid, and vitamin recommendations—alongside sports and physical activity plans tailored to the patient's cognitive and neurological profile. This aspect of Neuromap[®] ensures that patients' physical health supports their mental and neurological rehabilitation.

Educational and Professional Guidance: Neuromap® offers guidance on educational pathways

and career development, with a focus on the patient's cognitive abilities and learning needs. For individuals with autism spectrum disorder (ASD) and other conditions, Neuromap® provides specific recommendations based on international treatment programs such as Applied Behavior Analysis (ABA) and Cognitive Behavioral Therapy (CBT).

Age-Related Considerations: For older populations, Neuromap® even measures occipital alpha activity scores, which help identify risks of conditions such as Alzheimer's and dementia. This feature is particularly beneficial for adults over 30 who may be at increased risk of age-related cognitive decline.

Revolutionizing Personalized Treatment

Neuromap® stands at the forefront of personalized healthcare, leveraging artificial intelligence to provide detailed, actionable insights into brain function and health. This Al-driven solution enables healthcare providers to offer more precise and effective treatments for patients with a wide range of neurological conditions, from epilepsy and autism to Alzheimer's and dementia.

With Neuromap®, Cosmos Healthcare continues to push the boundaries of what is possible in modern medicine. The system's ability to synthesize complex neurological data into a clear and actionable format empowers both healthcare providers and patients, ensuring that treatment plans are more targeted, effective, and holistic.

About Cosmos Healthcare

Cosmos Healthcare is an industry leader in Al-powered healthcare innovations, dedicated to improving patient outcomes through advanced technology and personalized care solutions. Under the guidance of Dr. Alptekin Aydin, the team at Cosmos Healthcare is committed to integrating cutting-edge research and clinical expertise into real-world healthcare applications.

Damien Hayward
Editor Special News
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
TikTok
Other

This press release can be viewed online at: https://www.einpresswire.com/article/749279485

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.